Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Murtha

Physician Assistant West Islip, NY Physician Assistant

NPI 1861044612 CMS profile 11094387

540 Union Blvd, West Islip, NY 11795

Open in the dashboard

General payments

$4,768

114 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Murtha of West Islip, NY is reported in the CMS Open Payments database as having received $4,768 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $987 30
2024 General $2,084 38
2023 General $985 30
2022 General $649 13
2021 General $63 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Murtha
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kelly Murtha were reported at $987. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kelly Murtha Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $63 $132 $37–$438 $132
2022 $649 $155 $48–$522 $149
2023 $985 $167 $52–$557 $160
2024 $2,084 $178 $55–$600 $164
2025 $987 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,069 15 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $551 16 payments
  3. Merck Sharp & Dohme Corporation $450 18 payments
  4. E.R. Squibb & Sons, L.L.C. $353 8 payments
  5. Janssen Pharmaceuticals, Inc $346 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $336 7 payments
  7. AstraZeneca Pharmaceuticals LP $308 5 payments
  8. Novartis Pharmaceuticals Corporation $306 13 payments
  9. Novo Nordisk Inc $302 5 payments
  10. Kestra Medical Technology Services, Inc. $173 1 payment
  11. Other $575 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,322 112 payments
  2. Travel and Lodging $427 1 payment
  3. Education $19 1 payment
Products named General payments · program years 2021–2025
  1. WATCHMAN FLX $954 12 payments
  2. LifeVest $551 16 payments
  3. VERQUVO Cardiovascular $530 22 payments
  4. XARELTO $346 5 payments
  5. LEQVIO $306 13 payments
  6. JARDIANCE $294 5 payments
  7. FARXIGA $285 4 payments
  8. CAMZYOS $277 4 payments
  9. VERQUVO Cardiovascular $258 8 payments
  10. Assure WCD $173 1 payment
  11. Other $1,113 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

14,671

Median for Physician Assistant: 241

Drug cost

$3,356,267

Median for Physician Assistant: $4,110

Branded share of claims

30.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 907 $1,093,696
Entresto Sacubitril/Valsartan Brand 366 $514,929
Xarelto Rivaroxaban Brand 394 $494,039
Repatha Sureclick Evolocumab Brand 314 $303,341
Farxiga Dapagliflozin Propanediol Brand 151 $208,613
Jardiance Empagliflozin Brand 106 $161,167
Praluent Pen Alirocumab Brand 96 $101,753
Brilinta Ticagrelor Brand 76 $64,928
Multaq Dronedarone Hcl Brand 18 $35,168
Vascepa Icosapent Ethyl Brand 58 $32,631

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$15,279

Medicare's payments for the services billed

Medicare patients

301

Average age 78

Services billed

593

180 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 61%
Diabetes 49%
Atrial fibrillation 39%
Heart failure 38%
Chronic kidney disease 35%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $139
$139 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $138
$138 151 —
INJECTAFER
  • Daiichi Sankyo Inc. $104
$104 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $99
$99 394 —
VERQUVO
  • Merck Sharp & Dohme Corporation $80
$80 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record